Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower od ...

The intense demand for GLP-1 agonists stems from their proven efficacy in managing type 2 diabetes and, increasingly, in facilitating significant weight loss. However, patients often face substantial ...

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based ...

A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...